I'm perfectly agree. I continue to read posts in which the blame...

I'm perfectly agree.
I continue to read posts in which the blame for the drop in price per share is largely attributed to the delay in the start of phase 3 at Acadia's hands and its relative financial reliability. Once again I read the agreement with Acadia I find nothing inconsistent between what has been put in black and white in the contract and what Treagus communicated to shareholders in the ASM on 18 June last; it was already announced at the time of a delay due to the production of the drug (which would have been equal to the commercial) to start phase 3 that slipped to the second part of 2019. the delay had therefore already been announced and the price per share was just under $ 3. I have also studied in depth Acadia's numbers and insider purchases in the period of exclusive agreement and there is no particular concern both in terms of liquidity and any propensity to provide it with out-of-market investments.
What I continue to perceive as important signals already of the speech of June 18 is the particular attention of the company in marking the full funding in the short to progress in the preclinical of NNZ-2591, the patents that cover it long course and the great potential that could derive from the FDA granting of rare pediatric diseases. this last point was clearly expressed in the context of the announcement of partnership with Acadia.
I continue to have strong perplexities on the true motive of such a marked collapse and I expect that very soon returns rationality and consistency in the share course of the title.